Forristal, C E
Nowlan, B
Jacobsen, R N
Barbier, V
Walkinshaw, G
Walkley, C R
Winkler, I G
Levesque, J P
Article History
Received: 15 July 2014
Revised: 28 November 2014
Accepted: 18 December 2014
First Online: 12 January 2015
Competing interests
: GW is an employee of and owns equity in FibroGen Inc., which owns the commercial rights to FG-4497, PHI-1 and PH-2. FibroGen provided funding for experiments with PHI-1 and PHI-2. JPL and IGW are the inventors of a US patent describing these results.